Capital World Investors Grows Holdings in Abbott Laboratories $ABT

Capital World Investors boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,927,102 shares of the healthcare product maker’s stock after acquiring an additional 43,576 shares during the period. Capital World Investors owned 0.51% of Abbott Laboratories worth $1,195,680,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Capital International Sarl raised its stake in Abbott Laboratories by 4.2% during the third quarter. Capital International Sarl now owns 308,147 shares of the healthcare product maker’s stock valued at $41,273,000 after buying an additional 12,412 shares during the last quarter. Capital International Inc. CA grew its stake in shares of Abbott Laboratories by 17.5% in the third quarter. Capital International Inc. CA now owns 965,236 shares of the healthcare product maker’s stock worth $129,284,000 after acquiring an additional 144,033 shares during the last quarter. Capital International Investors increased its holdings in shares of Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares in the last quarter. Legal & General Group Plc raised its position in shares of Abbott Laboratories by 7.2% in the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock worth $1,727,869,000 after purchasing an additional 864,531 shares during the last quarter. Finally, Pinkerton Wealth LLC boosted its stake in Abbott Laboratories by 7.5% in the 3rd quarter. Pinkerton Wealth LLC now owns 41,287 shares of the healthcare product maker’s stock worth $5,530,000 after purchasing an additional 2,869 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ABT. The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Evercore reduced their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Piper Sandler reduced their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Finally, Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.37.

Abbott Laboratories Stock Down 1.8%

Shares of ABT opened at $110.60 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $192.18 billion, a P/E ratio of 29.73, a P/E/G ratio of 1.79 and a beta of 0.74. The firm has a fifty day moving average price of $115.55 and a 200-day moving average price of $124.29. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Transactions at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.